<p>Alpha Cognition Inc（ACOG）已举行其 2023 年第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>认识您的 ETF 人工智能分析师</h3>
<ul>
<li>了解 TipRanks 的_ETF_人工智能分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong>_ETF_人工智能分析师</strong> 对您关注的 ETF 所揭示的见解。</li>
</ul>
<p>Alpha Cognition Inc 最近的财报电话会议描绘了强劲的积极势头，主要得益于 ZUNVEYL 销售的显著增长和市场参与度的提升。尽管公司面临运营亏损和有限的支付方覆盖等挑战，但其财务状况依然稳健。</p>
<h2>ZUNVEYL 销售增长</h2>
<p>2025 年第三季度，ZUNVEYL 的销售额显著增长。出厂采购环比增长 44%，而需求销售瓶的发放量较上季度增长了惊人的 102%。这一激增凸显了市场对 ZUNVEYL 的接受度和需求的不断增长。</p>
<h2>在长期护理市场的成功参与</h2>
<p>Alpha Cognition 在长期护理市场取得了显著进展，在第三季度与 2,038 个家庭进行了接触，使其总覆盖家庭数达到 2,942 个独特家庭。值得注意的是，这些家庭中有 70% 进行了重复订购，突显了该产品的接受度及在该领域持续增长的潜力。</p>
<h2>积极的临床反馈</h2>
<p>ZUNVEYL 获得了积极的临床反馈，报告显示认知能力有所改善，且不良事件发生率较低。该产品的胃肠道不良事件发生率保持在低个位数，这为其安全性提供了良好的指示。</p>
<h2>强劲的财务状况</h2>
<p>公司的财务健康状况得益于通过股权发行筹集了 3,800 万美元的净收益。这笔资金的注入将 Alpha Cognition 的运营时间延长至 2027 年，为未来的增长计划提供了坚实的基础。</p>
<h2>研发进展</h2>
<p>Alpha Cognition 正在推进其研发工作，计划启动两个研究项目，CONVERGE 和 BEACON。这些研究旨在进一步评估 ZUNVEYL 的认知益处和耐受性，预计将在 2026 年底完成。</p>
<h2>运营亏损</h2>
<p>尽管有积极的发展，Alpha Cognition 在本季度报告了 530 万美元的运营亏损，较去年同期的 250 万美元有所增加。这一增长归因于销售、一般和行政（SG&amp;A）成本的上升。</p>
<h2>支付方覆盖的挑战</h2>
<p>公司在确保 ZUNVEYL 的更广泛支付方覆盖方面仍面临挑战。目前，只有 15% 的业务线在没有限制的情况下覆盖该产品，这需要持续努力来应对支付方的障碍。</p>
<h2>高运营费用</h2>
<p>总运营费用增加至 820 万美元，反映出与商业推出活动相关的更高成本。这一费用的上升突显了公司在扩大市场影响力方面的投资。</p>
<h2>前瞻性指导</h2>
<p>展望未来，Alpha Cognition 预计随着市场准入的扩大，ZUNVEYL 的销售将持续增长。公司预计 2025 年的全年运营费用将在 2800 万至 3000 万美元之间，较之前的指导有所下降，原因在于成本控制和运营效率的提升。尽管当前存在运营亏损，但衍生负债和利息收入的改善帮助将净亏损减少至 130 万美元。</p>
<p>总之，Alpha Cognition 的财报电话会议强调了强劲的积极发展轨迹，得益于稳健的销售增长和战略市场参与。尽管运营亏损和有限的支付方覆盖等挑战依然存在，但公司的稳健财务状况和前瞻性举措为未来的增长提供了良好的前景。</p>

ACOG

<p>Alpha Cognition Inc. 报告了强劲的 2025 年第三季度业绩，得益于 ZUNVEYL 销售增长 44% 和显著的市场参与。该公司与 2,038 家长期护理机构进行了合作，其中 70% 进行了重复订购。尽管运营亏损为 530 万美元，但 Alpha Cognition 的财务健康状况得益于 3,800 万美元的股权收益，使其运营时间延长至 2027 年。面临的挑战包括高运营费用和有限的支付方覆盖。该公司计划启动两个研究项目，CONVERGE 和 BEACON，以进一步评估 ZUNVEYL 的益处，预计将在 2026 年底完成</p>

<p>Alpha Cognition Inc ((ACOG)) has held its Q3 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Alpha Cognition Inc（ACOG）已举行其 2023 年第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF 人工智能分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的_ETF_人工智能分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong>_ETF_人工智能分析师</strong> 对您关注的 ETF 所揭示的见解。</li>
</ul>
</div><p>The latest earnings call from Alpha Cognition Inc. painted a picture of strong positive momentum, driven by significant growth in ZUNVEYL sales and increased market engagement. The company is supported by a robust financial position, although it faces challenges such as operating losses and limited payer coverage.</p>
<div class="lb-trans"><p>Alpha Cognition Inc 最近的财报电话会议描绘了强劲的积极势头，主要得益于 ZUNVEYL 销售的显著增长和市场参与度的提升。尽管公司面临运营亏损和有限的支付方覆盖等挑战，但其财务状况依然稳健。</p>
</div><h2>Sales Growth of ZUNVEYL</h2>
<div class="lb-trans"><h2>ZUNVEYL 销售增长</h2>
</div><p>The third quarter of 2025 was marked by a remarkable increase in sales for ZUNVEYL. Ex-factory purchases rose by 44% quarter-over-quarter, while demand sales bottles dispensed grew by an impressive 102% from the previous quarter. This surge underscores the growing market acceptance and demand for ZUNVEYL.</p>
<div class="lb-trans"><p>2025 年第三季度，ZUNVEYL 的销售额显著增长。出厂采购环比增长 44%，而需求销售瓶的发放量较上季度增长了惊人的 102%。这一激增凸显了市场对 ZUNVEYL 的接受度和需求的不断增长。</p>
</div><h2>Successful Engagement in Long-Term Care Market</h2>
<div class="lb-trans"><h2>在长期护理市场的成功参与</h2>
</div><p>Alpha Cognition made significant strides in the long-term care market, engaging with 2,038 homes in Q3, bringing their total reach to 2,942 unique homes. Notably, 70% of these homes placed repeat orders, highlighting the product’s acceptance and potential for sustained growth in this sector.</p>
<div class="lb-trans"><p>Alpha Cognition 在长期护理市场取得了显著进展，在第三季度与 2,038 个家庭进行了接触，使其总覆盖家庭数达到 2,942 个独特家庭。值得注意的是，这些家庭中有 70% 进行了重复订购，突显了该产品的接受度及在该领域持续增长的潜力。</p>
</div><h2>Positive Clinical Feedback</h2>
<div class="lb-trans"><h2>积极的临床反馈</h2>
</div><p>ZUNVEYL has received positive clinical feedback, with reports indicating improvements in cognition and a low incidence of adverse events. The product maintains a low single-digit rate of gastrointestinal adverse events, which is a promising indicator of its safety profile.</p>
<div class="lb-trans"><p>ZUNVEYL 获得了积极的临床反馈，报告显示认知能力有所改善，且不良事件发生率较低。该产品的胃肠道不良事件发生率保持在低个位数，这为其安全性提供了良好的指示。</p>
</div><h2>Strong Financial Position</h2>
<div class="lb-trans"><h2>强劲的财务状况</h2>
</div><p>The company’s financial health is bolstered by raising $38 million in net proceeds through an equity offering. This capital infusion extends Alpha Cognition’s operational runway into 2027, providing a solid foundation for future growth initiatives.</p>
<div class="lb-trans"><p>公司的财务健康状况得益于通过股权发行筹集了 3,800 万美元的净收益。这笔资金的注入将 Alpha Cognition 的运营时间延长至 2027 年，为未来的增长计划提供了坚实的基础。</p>
</div><h2>Progress in Research and Development</h2>
<div class="lb-trans"><h2>研发进展</h2>
</div><p>Alpha Cognition is advancing its research and development efforts with plans to initiate two studies, CONVERGE and BEACON. These studies aim to further assess ZUNVEYL’s cognitive benefits and tolerability, with completion expected by late 2026.</p>
<div class="lb-trans"><p>Alpha Cognition 正在推进其研发工作，计划启动两个研究项目，CONVERGE 和 BEACON。这些研究旨在进一步评估 ZUNVEYL 的认知益处和耐受性，预计将在 2026 年底完成。</p>
</div><h2>Operating Loss</h2>
<div class="lb-trans"><h2>运营亏损</h2>
</div><p>Despite the positive developments, Alpha Cognition reported an operating loss of $5.3 million for the quarter, up from $2.5 million in the same period last year. This increase is attributed to higher selling, general, and administrative (SG&amp;A) costs.</p>
<div class="lb-trans"><p>尽管有积极的发展，Alpha Cognition 在本季度报告了 530 万美元的运营亏损，较去年同期的 250 万美元有所增加。这一增长归因于销售、一般和行政（SG&amp;A）成本的上升。</p>
</div><h2>Challenges with Payer Coverage</h2>
<div class="lb-trans"><h2>支付方覆盖的挑战</h2>
</div><p>The company continues to face challenges in securing broader payer coverage for ZUNVEYL. Currently, only 15% of business lines cover the product without restrictions, necessitating ongoing efforts to navigate payer obstacles.</p>
<div class="lb-trans"><p>公司在确保 ZUNVEYL 的更广泛支付方覆盖方面仍面临挑战。目前，只有 15% 的业务线在没有限制的情况下覆盖该产品，这需要持续努力来应对支付方的障碍。</p>
</div><h2>High Operating Expenses</h2>
<div class="lb-trans"><h2>高运营费用</h2>
</div><p>Total operating expenses increased to $8.2 million, reflecting the higher costs associated with commercial launch activities. This rise in expenses underscores the company’s investment in expanding its market presence.</p>
<div class="lb-trans"><p>总运营费用增加至 820 万美元，反映出与商业推出活动相关的更高成本。这一费用的上升突显了公司在扩大市场影响力方面的投资。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Looking ahead, Alpha Cognition anticipates continued growth in ZUNVEYL sales as they expand market access. The company expects full-year operating expenses for 2025 to be between $28 million and $30 million, a decrease from prior guidance due to cost discipline and operational efficiency. Despite the current operating loss, improvements in derivative liabilities and interest income have helped reduce the net loss to $1.3 million.</p>
<div class="lb-trans"><p>展望未来，Alpha Cognition 预计随着市场准入的扩大，ZUNVEYL 的销售将持续增长。公司预计 2025 年的全年运营费用将在 2800 万至 3000 万美元之间，较之前的指导有所下降，原因在于成本控制和运营效率的提升。尽管当前存在运营亏损，但衍生负债和利息收入的改善帮助将净亏损减少至 130 万美元。</p>
</div><p>In summary, Alpha Cognition’s earnings call highlighted a strong positive trajectory, driven by robust sales growth and strategic market engagement. While challenges such as operating losses and limited payer coverage persist, the company’s solid financial position and forward-looking initiatives provide a promising outlook for future growth.</p>
<div class="lb-trans"><p>总之，Alpha Cognition 的财报电话会议强调了强劲的积极发展轨迹，得益于稳健的销售增长和战略市场参与。尽管运营亏损和有限的支付方覆盖等挑战依然存在，但公司的稳健财务状况和前瞻性举措为未来的增长提供了良好的前景。</p>
</div>

Alpha Cognition 的财报电话会议：销售强劲且战略性增长